Fuxtil CV250 mg+62.50 mg

Fuxtil CV 250 mg+62.50 mg is a combination antibiotic indicated for the treatment of mild to moderate bacterial infections caused by susceptible organisms, including beta-lactamase-producing strains that are resistant to Cefuroxime alone. The addition of Clavulanic Acid significantly broadens the antibacterial spectrum, making this combination effective against a wide range of pathogens.

Ear, Nose & Throat (ENT) Infections

• Pharyngitis and Tonsillitis caused by Streptococcus pyogenes.
• Acute Bacterial Otitis Media (middle ear infection) caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (including beta-lactamase-producing strains), and Streptococcus pyogenes.
• Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase-producing strains).

Respiratory Tract Infections

• Lower Respiratory Tract Infections including Pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, and Escherichia coli.
• Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase-negative strains), or Haemophilus parainfluenzae (beta-lactamase-negative strains).
• Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Haemophilus parainfluenzae.

Skin and Soft Tissue Infections

• Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase-producing strains) or Streptococcus pyogenes.

Urinary Tract Infections

• Uncomplicated Urinary Tract Infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae.

Bone and Joint Infections

• Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains).

Sexually Transmitted Infections

• Uncomplicated Gonorrhoea caused by penicillinase-producing and non-penicillinase-producing strains of Neisseria gonorrhoeae.

Vector-Borne and Systemic Infections

• Early Lyme Disease (Erythema Migrans) caused by Borrelia burgdorferi.
• Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp.
• Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis, and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains).

Switch Therapy

Fuxtil CV 250 mg+62.50 mg is also used in switch therapy — transitioning patients from parenteral (injectable) cephalosporin therapy to oral therapy once clinical improvement is observed. This approach reduces hospital stay and healthcare costs while maintaining therapeutic efficacy.

Always take this medication as directed by a registered physician.

Mechanism of Action

Cefuroxime Axetil

Cefuroxime is a second-generation cephalosporin antibiotic with bactericidal activity against a broad spectrum of Gram-positive and Gram-negative bacteria. It exerts its antibacterial effect by inhibiting bacterial cell wall synthesis. Specifically, Cefuroxime binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall and interferes with the transpeptidation process — a critical step in the cross-linking of peptidoglycan chains. Without a functional cell wall, the bacterium becomes structurally unstable and undergoes rapid lysis and death.

Cefuroxime Axetil is the oral prodrug form of Cefuroxime. After oral ingestion, it is absorbed from the gastrointestinal tract and rapidly hydrolyzed by non-specific esterases in the intestinal mucosa and blood to release the active form, Cefuroxime, into systemic circulation.

Clavulanic Acid

Clavulanic Acid is a naturally derived beta-lactamase inhibitor produced by the bacterium Streptomyces clavuligerus. Although it has weak intrinsic antibacterial activity on its own, it possesses a beta-lactam ring structure that closely resembles that of penicillins and cephalosporins. This structural similarity allows Clavulanic Acid to act as a competitive, irreversible (suicide) inhibitor of beta-lactamase enzymes — bacterial enzymes responsible for breaking down and inactivating beta-lactam antibiotics.

By irreversibly binding to and inactivating these beta-lactamase enzymes, Clavulanic Acid protects Cefuroxime from enzymatic degradation, effectively restoring and extending its antibacterial potency against resistant organisms that would otherwise destroy the antibiotic before it could act.

Synergistic Effect

The combination of Cefuroxime and Clavulanic Acid produces a synergistic antibacterial effect. While Cefuroxime destroys the bacteria, Clavulanic Acid shields it from resistance mechanisms. This dual-action approach provides effective treatment for infections caused by beta-lactam-resistant bacteria — including many strains of Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Klebsiella species — that would not respond to Cefuroxime alone.

Pharmacokinetics

• Absorption: Cefuroxime Axetil is well absorbed orally. Bioavailability is enhanced when taken with food (postprandial absorption is superior). Clavulanic Acid is also well absorbed from the gastrointestinal tract.
• Distribution: Cefuroxime distributes widely into body tissues and fluids, including lungs, bone, synovial fluid, and pleural fluid. It crosses the blood-brain barrier in the presence of meningeal inflammation.
• Metabolism: Cefuroxime Axetil is hydrolyzed to active Cefuroxime post-absorption. Clavulanic Acid undergoes extensive hepatic metabolism.
• Elimination: Cefuroxime is primarily excreted unchanged via the kidneys through glomerular filtration and tubular secretion. Clavulanic Acid is excreted both renally and via non-renal routes. Dose adjustments may be necessary in patients with renal impairment.
• Half-life: Approximately 1–1.5 hours for Cefuroxime under normal renal function. The combination has an average effect duration of 4–8 hours.

Correct administration of Fuxtil CV 250 mg+62.50 mg is essential for achieving optimal therapeutic outcomes and minimizing side effects. Follow your doctor's instructions carefully and refer to the guidance below.

Tablets

• With or without food: Fuxtil CV 250 mg+62.50 mg tablets may be taken regardless of meals. However, taking the tablet with food improves the absorption of Cefuroxime Axetil and may reduce the risk of nausea or stomach upset.
• Swallow whole: Swallow the tablet whole with a full glass of water (at least 200 mL). Do not crush, split, or chew the tablet unless specifically instructed by your doctor, as this may affect drug release and palatability.
• Dosing schedule: Twice-daily doses should be taken approximately 12 hours apart (e.g., 8 AM and 8 PM) to maintain consistent drug levels in the blood.

Oral Suspension (for Children)

• Reconstitution: Add the specified amount of water to the dry powder as indicated on the product label. Shake vigorously after adding water to ensure complete dissolution.
• Shake before use: Always shake the bottle well before measuring each dose.
• Accurate measuring: Use the calibrated dosing syringe or measuring spoon provided with the packaging. Do not use a household teaspoon, as it may not deliver the correct dose.
• With food: Giving the suspension to children with a meal or a snack can enhance absorption and reduce the risk of GI upset.
• Storage after reconstitution: Store in the refrigerator. Discard any unused suspension after the period specified on the label (typically 7–10 days).

Missed Dose

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to make up for the missed one, as this increases the risk of side effects.

Completing the Full Course

Always complete the full prescribed course of Fuxtil CV 250 mg+62.50 mg, even if you feel better before the course ends. Stopping treatment early may allow surviving bacteria to multiply and cause a relapse, and increases the risk of antibiotic resistance.

Do Not Share

Never share this antibiotic with others, even if they appear to have a similar infection. Antibiotic selection should always be based on culture sensitivity results and physician evaluation.

Take this medication only as prescribed by your registered physician. Do not self-diagnose or self-medicate.

Fuxtil CV 250 mg+62.50 mg may interact with certain drugs, altering their efficacy or increasing the risk of adverse effects. Inform your doctor or pharmacist about all medications, supplements, and herbal products you are currently taking before starting this combination.

Clinically Significant Interactions

1. Probenecid

Concurrent administration of Probenecid (a uricosuric agent used in gout) with Cefuroxime-Clavulanic Acid significantly increases the area under the serum concentration-time curve (AUC) of Cefuroxime by approximately 50%. Probenecid blocks the renal tubular secretion of Cefuroxime, thereby reducing its renal clearance and prolonging its plasma half-life. While this interaction may sometimes be exploited therapeutically to enhance antibiotic concentrations, it requires careful monitoring as elevated Cefuroxime levels may increase the risk of adverse effects.

2. Gastric Acid-Reducing Agents

Drugs that reduce gastric acidity — including antacids, H2-receptor antagonists (e.g., ranitidine, famotidine), and proton pump inhibitors (e.g., omeprazole, pantoprazole) — may result in a lower bioavailability of Cefuroxime Axetil. Since an acidic gastric environment facilitates the dissolution and absorption of Cefuroxime Axetil, reduced acidity impairs its absorption. Additionally, these agents tend to cancel out the beneficial effect of postprandial (post-meal) absorption enhancement. If co-administration is necessary, the timing and clinical impact should be considered.

Other Potential Interactions to Consider

3. Oral Anticoagulants (e.g., Warfarin)

As with other broad-spectrum antibiotics, Cefuroxime-Clavulanic Acid may alter the intestinal flora responsible for synthesizing Vitamin K, potentially enhancing the anticoagulant effect of drugs like Warfarin. Patients on oral anticoagulants should have their INR (International Normalized Ratio) monitored more closely during and after antibiotic therapy.

4. Live Bacterial Vaccines

Cefuroxime-Clavulanic Acid, like other antibiotics, may reduce the effectiveness of live attenuated bacterial vaccines (e.g., oral typhoid vaccine) by killing the vaccine organisms. Avoid concurrent use; consult your physician regarding appropriate timing of vaccination.

5. Loop Diuretics (e.g., Furosemide)

Concomitant use with potent loop diuretics may increase the risk of nephrotoxicity. Patients receiving both drugs should be monitored for signs of renal dysfunction.

This is not an exhaustive list of all possible drug interactions. Always consult a registered physician or pharmacist before combining medications.

Fuxtil CV 250 mg+62.50 mg is generally well tolerated when used at the recommended doses and duration. However, like all antibiotics, it may cause side effects in some patients. The majority of adverse effects are mild to moderate and resolve after completing the course of treatment.

Common Side Effects

The following side effects are relatively common and affect a notable proportion of patients:

• Nausea — a feeling of discomfort or urge to vomit, especially when taken on an empty stomach.
• Vomiting — may occur alongside nausea, particularly at higher doses.
• Diarrhea — one of the most frequently reported gastrointestinal side effects. Taking probiotics alongside the antibiotic may help reduce this.
• Abdominal Discomfort or Pain — cramping or general abdominal unease may occur during the treatment course.

Less Common Side Effects

• Headache
• Dizziness
• Vaginal candidiasis (thrush) — due to disruption of normal vaginal flora during prolonged antibiotic use.
• Altered taste — some patients may notice a bitter or metallic taste.
• Elevated liver enzymes — usually transient and reversible.

Rare but Serious Side Effects (<0.2%)

The following adverse effects are rare but may be serious and require immediate medical attention:

• Renal Dysfunction — impaired kidney function, especially in patients with pre-existing renal conditions or those on concomitant nephrotoxic drugs.
• Anaphylaxis — a severe, life-threatening allergic reaction characterized by difficulty breathing, drop in blood pressure, and cardiovascular collapse. Requires emergency treatment.
• Angioedema — rapid swelling of the face, lips, tongue, throat, or limbs. Seek emergency care immediately.
• Pruritus (itching) — generalized or localized skin itching, which may be an early sign of an allergic reaction.
• Skin Rash — ranging from mild urticaria (hives) to more severe forms such as Stevens-Johnson syndrome (in extremely rare cases).
• Serum Sickness-Like Urticaria — a delayed hypersensitivity reaction presenting with rash, fever, and joint pain.
• Pseudomembranous Colitis — severe, watery or bloody diarrhea caused by Clostridioides difficile overgrowth following disruption of gut flora. Discontinue immediately and seek medical care.

Superinfection Risk

As with other broad-spectrum antibiotics, prolonged administration of Fuxtil CV 250 mg+62.50 mg may result in the overgrowth of non-susceptible microorganisms, including fungi (e.g., Candida species) or resistant bacteria. If superinfection occurs, appropriate therapy should be initiated.

When to Seek Immediate Medical Attention

• You develop difficulty breathing, swelling of the face or throat, or a sudden drop in blood pressure (signs of anaphylaxis).
• You notice bloody or watery stools — this may indicate C. difficile-associated diarrhea.
• You develop a widespread, blistering, or peeling rash.
• You experience yellowing of the skin or eyes (jaundice), which may indicate liver involvement.

Report any unexpected or persistent side effects to your doctor or pharmacist promptly.

Use During Pregnancy

As a general principle, all antibiotics — including Fuxtil CV 250 mg+62.50 mg — should be avoided during the first trimester of pregnancy whenever possible, as the developing fetus is most vulnerable during organogenesis (weeks 3–8). However, untreated bacterial infections in pregnancy can pose significant risks to both the mother and the fetus, including preterm labor, intrauterine growth restriction, and sepsis.

Fuxtil CV 250 mg+62.50 mg can be safely used during the second and third trimesters of pregnancy when clinically indicated — particularly for the treatment of urinary tract infections, respiratory infections, and other bacterial conditions that commonly arise during pregnancy. Multiple clinical studies and post-marketing data support its use as a relatively safe antibiotic option in later pregnancy.

Pregnancy Category: Cefuroxime is classified as a Category B drug by the US FDA, meaning animal reproduction studies have not demonstrated fetal risk, and there are no well-controlled studies in pregnant women — or animal studies have shown adverse effects, but well-controlled studies in pregnant women have not confirmed this risk.

Always consult a registered physician before taking any antibiotic during pregnancy. Self-medication is not recommended.

Use During Breastfeeding (Lactation)

Fuxtil CV 250 mg+62.50 mg is excreted into breast milk in small quantities. While the concentrations transferred to the nursing infant are generally considered low and unlikely to cause direct harm, there are potential concerns that should be discussed with a healthcare provider:

• Risk of Sensitization: Although the amount of drug in breast milk is small, there is a possibility of sensitizing the infant to cephalosporins or Clavulanic Acid. Future exposure to related antibiotics could then trigger an allergic reaction.
• Disruption of Infant Gut Flora: Even small quantities of antibiotics in breast milk may alter the infant's intestinal microbiome, potentially causing loose stools or mild diarrhea in the nursing baby.
• Oral Thrush: Rarely, the infant may develop oral or diaper-area candidiasis (thrush) due to gut flora disruption.

In most cases, the benefits of continuing breastfeeding while treating a bacterial infection in the mother outweigh the minimal risks to the infant. The decision should be made collaboratively between the mother and her healthcare provider, taking into account the severity of the infection, the duration of treatment, and the age and health of the infant.

Monitor the breastfed infant for unusual fussiness, diarrhea, or rash during the mother's antibiotic course and consult a physician if any concerns arise.

Before starting treatment with Fuxtil CV 250 mg+62.50 mg, patients and healthcare providers should carefully consider the following precautions to ensure safe and effective use.

1. History of Allergic Reactions

Carefully evaluate any history of hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactam antibiotics. Patients with a history of severe penicillin allergy (particularly anaphylaxis) should be assessed carefully before receiving cephalosporin therapy due to the possibility of cross-reactivity. In case of any allergic signs or symptoms, the drug should be discontinued immediately and appropriate emergency treatment initiated.

2. History of Gastrointestinal Disease / Colitis

Fuxtil CV 250 mg+62.50 mg should be given with care to patients with a history of colitis or inflammatory bowel conditions. Broad-spectrum antibiotic use can disrupt the normal colonic flora and predispose patients to Clostridioides difficile-associated diarrhea (CDAD) and pseudomembranous colitis. If severe diarrhea or bloody stools occur during or after treatment, immediately discontinue the drug and seek medical evaluation.

3. Concomitant Use of Potent Diuretics

Cefuroxime should be administered with caution in patients receiving concurrent treatment with potent diuretics (e.g., furosemide, ethacrynic acid), as the combination may increase the risk of nephrotoxicity. Regular monitoring of renal function is advisable in such patients, particularly during prolonged therapy.

4. Renal Impairment

Since Cefuroxime is primarily eliminated by the kidneys, patients with moderate to severe renal impairment (creatinine clearance <30 mL/min) require dose reduction and extended dosing intervals to prevent drug accumulation and toxicity. Renal function should be monitored during therapy in at-risk patients.

5. Hepatic Impairment

Clavulanic Acid undergoes hepatic metabolism. Use with caution in patients with pre-existing liver disease or hepatic impairment. Rare cases of hepatitis and cholestatic jaundice have been associated with Clavulanic Acid-containing antibiotics. Discontinue treatment if signs of hepatic dysfunction appear.

6. Superinfection

Prolonged or repeated use of Fuxtil CV 250 mg+62.50 mg may result in the overgrowth of non-susceptible organisms (bacteria or fungi), leading to a secondary (superinfection). If superinfection occurs during therapy, appropriate measures should be taken, including dose adjustment or switching to an alternative regimen.

7. Antibiotic Resistance

This antibiotic combination should only be used for bacterial infections confirmed or strongly suspected to be caused by susceptible organisms. Inappropriate or unnecessary use contributes to the development of antibiotic resistance, rendering effective treatments unavailable for future patients.

8. Completion of Full Treatment Course

Do not stop taking Fuxtil CV 250 mg+62.50 mg prematurely, even if you feel better. Stopping treatment early may allow remaining bacteria to multiply, cause a relapse of the infection, and potentially develop resistance to the antibiotic.

9. Alcohol Interaction

The interaction between this combination and alcohol is not fully established. As a precautionary measure, consult your doctor before consuming alcohol during the treatment period.

10. Use in Elderly Patients

Elderly patients may have reduced renal function, which can alter drug clearance. Monitor renal function in older adults and adjust doses accordingly.

Disclose your complete medical history, including all current medications and supplements, to your physician before starting this antibiotic.

Overview

Overdose with Fuxtil CV 250 mg+62.50 mg is uncommon but can occur, particularly in cases of accidental ingestion by children, or when dosage instructions are not followed. Cephalosporin overdoses are generally associated with a low risk of severe life-threatening toxicity, but prompt medical attention is still warranted.

Signs and Symptoms of Overdose

Excessive doses of Fuxtil CV 250 mg+62.50 mg may cause the following symptoms:

• Gastrointestinal disturbances — nausea, vomiting, abdominal pain, and diarrhea are the most commonly reported symptoms in overdose situations.
• Neurological effects — at very high concentrations, cephalosporins may cause neurotoxic effects including agitation, confusion, tremors, or convulsions (seizures), particularly in patients with renal impairment who are unable to eliminate the drug efficiently.
• Renal toxicity — elevated serum creatinine and reduced urine output may occur, especially in patients with pre-existing kidney disease.
• Electrolyte imbalances — large doses may affect serum electrolytes.

Management of Overdose

There is no specific antidote for Fuxtil CV 250 mg+62.50 mg overdose. Management is symptomatic and supportive:

• Discontinue the drug immediately upon suspicion of overdose.
• Seek emergency medical care — contact a poison control center or go to the nearest emergency department.
• Gastric decontamination — if overdose was recent (within 1–2 hours) and the patient is conscious, activated charcoal may be considered by medical personnel to reduce drug absorption.
• Supportive therapy — maintain adequate hydration, monitor renal function, electrolyte levels, and neurological status.
• Hemodialysis — Cefuroxime is dialyzable, so hemodialysis may be considered in severe cases, especially in patients with renal failure, to enhance drug elimination.
• Seizure management — if convulsions occur, standard anticonvulsant therapy should be initiated under medical supervision.

Prevention

• Always take the exact dose prescribed by your physician.
• Store medication out of the reach of children.
• Do not double the dose if you miss one — take it as soon as you remember, or skip it if it is almost time for the next dose.

In case of suspected overdose, contact your nearest Poison Control Center or Emergency Department immediately. Do not attempt to treat an overdose at home without professional guidance.

General Storage Instructions

• Store in a cool, dry place at a temperature below 30°C (86°F).
• Protect from direct sunlight, excessive heat, and moisture. Do not store in bathrooms or near kitchen sinks where humidity is high.
• Keep the medication in its original packaging or tightly closed container to protect it from environmental exposure.
• Keep out of the reach and sight of children at all times. Accidental ingestion by children can lead to overdose.
• Do not refrigerate unless specifically directed by the manufacturer or pharmacist (some oral suspensions may require refrigeration — check the product label).

Oral Suspension (Reconstituted)

• Once reconstituted (mixed with water), the oral suspension should generally be stored in the refrigerator (2°C–8°C / 36°F–46°F).
• The reconstituted suspension should be discarded after 7–10 days (as specified on the product labeling) even if some medication remains.
• Do not freeze the reconstituted suspension.
• Shake well before each use.

Tablets

• Store tablets at below 30°C in a dry location away from moisture and light.
• Keep tablets in their blister packs or original container until immediately before use.
• Do not use tablets beyond the expiry date printed on the packaging.

Disposal

• Do not flush unused medication down the toilet or pour it into drains unless specifically instructed to do so.
• Dispose of expired or unused medication through a medicine take-back program or as directed by your local pharmacy or healthcare authority.
• Do not use leftover medication for future infections without consulting a doctor first, as the type of bacteria or appropriate antibiotic may differ.

Always check the product label and package insert for storage instructions specific to your formulation, as requirements may vary between manufacturers.

1. Paediatric Patients (Children)

Fuxtil CV 250 mg+62.50 mg is approved for use in children aged 3 months and older. The oral suspension formulation (125 mg + 31.25 mg per 5 ml) is suitable for paediatric use and allows accurate weight-based dosing.

• Doses are calculated per kilogram of body weight (mg/kg/day), divided into twice-daily administrations.
• Safety and efficacy in infants below 3 months of age have not been established; use in this age group is not recommended without specialist guidance.
• Monitor paediatric patients for diarrhea, rash, and signs of allergic reaction during treatment.

2. Elderly Patients

Elderly patients often have reduced renal clearance due to age-related decline in kidney function. As Cefuroxime is primarily renally eliminated, accumulation can occur in older adults.

• Assess renal function (eGFR or creatinine clearance) before initiating therapy in elderly patients.
• Dose adjustment may be necessary if renal function is significantly impaired (CrCl <30 mL/min).
• Monitor for signs of nephrotoxicity and neurotoxicity (confusion, tremors) in elderly patients on high doses or prolonged therapy.

3. Patients with Renal Impairment

Cefuroxime is excreted primarily by the kidneys. Patients with impaired renal function are at risk of drug accumulation, which may lead to adverse effects including neurotoxicity.

• Mild impairment (CrCl 30–80 mL/min): Standard doses are generally acceptable; monitor renal function.
• Moderate impairment (CrCl 10–30 mL/min): Dose reduction and extended dosing intervals are recommended. Consult physician.
• Severe impairment (CrCl <10 mL/min): Use with extreme caution. Consider alternative antibiotics. If used, significantly reduced doses are required.
• Dialysis patients: An additional dose should be given after each hemodialysis session as Cefuroxime is dialyzable.

4. Patients with Hepatic Impairment

Clavulanic Acid undergoes hepatic metabolism. While specific dosage adjustments are not routinely required for mild hepatic impairment, caution is advised in patients with severe liver disease.

• Monitor liver function tests (LFTs) periodically during prolonged use in patients with pre-existing hepatic conditions.
• Discontinue use if hepatitis or cholestatic jaundice develops.
• There is no established dosage recommendation for severe hepatic impairment; consult a hepatologist.

5. Immunocompromised Patients

Patients with weakened immune systems (e.g., HIV/AIDS, organ transplant recipients, patients on long-term corticosteroids or chemotherapy) may require closer monitoring. The risk of opportunistic infections and superinfections is higher in this group during antibiotic therapy. Culture and sensitivity testing are especially important before initiating treatment.

6. Patients with Seizure Disorders

High-dose cephalosporins have been associated with neurotoxic effects including seizures, particularly in patients with pre-existing epilepsy or renal impairment. Use Fuxtil CV 250 mg+62.50 mg with caution in patients with a history of seizures.